Compare ARVN & SCHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ARVN | SCHL |
|---|---|---|
| Founded | 2015 | 1920 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Books |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 600.2M | 672.6M |
| IPO Year | 2018 | 1995 |
| Metric | ARVN | SCHL |
|---|---|---|
| Price | $6.82 | $38.94 |
| Analyst Decision | Buy | |
| Analyst Count | 16 | 0 |
| Target Price | ★ $13.93 | N/A |
| AVG Volume (30 Days) | ★ 772.6K | 520.9K |
| Earning Date | 11-04-2026 | 09-24-2026 |
| Dividend Yield | N/A | ★ 2.55% |
| EPS Growth | 58.84 | ★ 3442.86 |
| EPS | ★ 1.70 | N/A |
| Revenue | $262,600,000.00 | ★ $1,487,100,000.00 |
| Revenue This Year | $12.76 | $2.14 |
| Revenue Next Year | N/A | $3.42 |
| P/E Ratio | $4.04 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $6.80 | $26.38 |
| 52 Week High | $14.22 | $48.07 |
| Indicator | ARVN | SCHL |
|---|---|---|
| Relative Strength Index (RSI) | 28.59 | 60.42 |
| Support Level | N/A | $37.84 |
| Resistance Level | $8.52 | $39.96 |
| Average True Range (ATR) | 0.30 | 1.63 |
| MACD | -0.03 | 0.61 |
| Stochastic Oscillator | 8.61 | 87.31 |
Arvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company is using its PROteolysis TArgeting Chimera, a protein degradation platform, to develop therapeutics designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Its clinical development program includes various product candidates such as ARV-102, ARV-806, ARV-393, ARV-027, and vepdegestrant, in their different stages of development, being developed to target certain harmful proteins causing oncology and neurology-related diseases.
Scholastic Corp is a publisher and distributor of children's books, a provider of print and digital instructional materials for grades pre-kindergarten (pre-K) to grade 12 and a producer of entertaining literary and educational children's media. The company creates quality print, digital and audio books, learning materials and programs, classroom magazines and other products that, in combination, offer children, families and educators engaging and comprehensive solutions to support children's learning and reading both at home and at school. It categorizes its businesses into four reportable segments: Children's Book Publishing and Distribution; Education; Entertainment; and International. It derives the majority of revenue from Children's Book Publishing and Distribution segment.